SingHealth Duke-NUS Vascular Centre

Synonym(s):

vascular centre 

The SingHealth Duke-NUS Vascular Centre (SDVC) was established in February 2021 to bring together the strengths of healthcare professionals from different specialities across SingHealth institutions to provide seamless and holistic patient-centric care.

 

Our clinical sites are located at:

 

Vascular diseases relate to disorders of the arteries, veins and lymphatics. Conditions requiring specialised vascular care include:

  • Peripheral vascular disease
  • Aortic aneurysms / dissections
  • Haemodialysis access and central venous stenosis/occlusions
  • Varicose veins
  • Venous occlusive / thrombo-embolic diseases (Deep venous thrombosis/pulmonary embolism)
  • Vascular anomalies (vascular tumours, vascular malformations and complex vascular anomalies síndromes)

 

The care for a vascular patient is often complex. This usually involves coordination by the primary clinician to ensure the medical, clinical, wound, dialysis, rehabilitation care needs are taken care of.

Many of the conditions can now be managed by minimally invasive endovascular procedures without the need for open surgery and many of these endovascular techniques have become the standard of care. Several specialists including vascular surgeons, cardiac surgeons, interventional radiologists, interventional nephrologists, and interventional cardiologists perform endovascular procedures to treat these conditions. The management of vascular anomalies is multi-disciplinary that includes dermatologists, interventional radiologists, surgeons and haemato-oncologists in both paediatric and adult patients.

The Centre will collaborate with researchers and educators from SingHealth institutions and Duke-NUS to deepen knowledge in the causes of vascular diseases, drive innovation to find better ways to diagnose and treat conditions and ensure healthcare professionals have the skills they need to provide the best care for patients.

Our Care Team

News

$25 million boost for Singapore-led research to improve lung cancer treatment for Asian patients
Awards $25 million boost for Singapore-led research to improve lung cancer treatment for Asian patients In a national effort to transform lung cancer care, the National Cancer Centre Singapore (NCCS), in collaboration with the Agency for Science, Technology and Research (A*STAR) and National University Cancer Institute, Singapore (NCIS), has been awarded a S$25 million grant by the Singapore Ministry of Health through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd, under the NMRC Open Fund-Large Collaborative Grant (OF-LCG) programme.
16 Jul 2025 Read Story
Research 本地团队获2500万元资助 研究非吸烟者肺癌防治方案 许爱棻36岁那年,在产后坐月子期间,被确诊患上第3B期肺癌。对从未吸过烟、也一向健康的她来说,这无异于晴天霹雳。从那一刻起,她便踏上与病魔缠斗的漫长旅程。
16 Jul 2025 | Lianhe Zaobao Read Story
Research Singapore researchers get $25m grant to screen, treat lung cancer in Asian patients Researchers here have received a $25 million grant to work on tackling lung cancer in Asian patients across all stages – from risk prediction and early detection of those who are at risk, to personalised treatments of patients at more advanced stages of the illness.
16 Jul 2025 | The Straits Times Read Story
Upcoming Events